Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SMMTBullishIndustry Newsnews

High materiality7/10

Ivonescimab data at ASCO boosts Summit's mCRC expansion prospects

May 30, 2026, 8:04 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong ORR/DCR signals and durable responses in a difficult MSS mCRC setting; immediate readthrough to Phase III strategy and HARMONi-GI3 could attract buyers, though execution risk remains until Phase III data materializes.

AI summary

What happened, with direct paths to the underlying reporting

Summit Therapeutics and Akeso reported Phase II AK112-206 results in first-line MSS metastatic colorectal cancer showing an ORR of 70.8% and a DCR of 100% when ivonescimab is combined with mFOLFOX6. The 20 mg/kg dose delivered more durable responses, with a 9-month PFS of 76.1% and a DOR of 79.1%. Safety remains manageable, with 20.4% serious TRAEs and no ivonescimab-related deaths, supporting further Phase III exploration via HARMONi-GI3.

Ivonescimab with mFOLFOX6 yields 70.8% ORR and 100% DCR in MSS mCRC.
20 mg/kg arm shows longer durability; 9-month PFS at 76.1%.
Safety is acceptable; 20.4% serious TRAEs; no ivonescimab-related deaths.
HARMONi-GI3 Phase III CRC trial highlighted as ASCO TiP.
Ivonescimab is a PD-1/VEGF bispecific with potential multi-tumor expansion.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Ivonescimab data at ASCO boosts Summit's mCRC expansion prospects

Summit Therapeutics dubbed 'great spec' by Cramer amid cash runway concerns

Ivonescimab OS reads strengthen data; FDA filing and cash runway extended

HARMONi trial data and FDA action date could lift SMMT shares

Summit HARMONi OS data boost ivonescimab; FDA date on track